Financial OutlookDynavax forecasts a robust financial future with expectations of becoming cash-flow positive, underpinned by solid revenue guidance for Heplisav.
Market PositionHeplisav-B, as the only two-dose adult Hepatitis-B vaccine, coupled with recent guideline changes, is poised to capture growing market opportunities.
Product PerformanceHeplisav-B sales rose significantly, with market share and gross margin continuing to expand, showcasing strong market adoption and financial health.